Article

Development and Optimization of 111In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma Resection

2026-08-31

Abstract excerpt

Rationale: Neuroblastoma is a devastating pediatric malignancy, for which surgical resection is a key factor in long-term survival. However, there are significant challenges in its resection, particularly in high-risk disease, as neuroblastoma encases surrounding critical structures, is often difficult to distinguish from desmoplastic or scar tissue, and can carry occult deposits of disease not readily identified...

Identifiers and source

Literature Corpus work: cce96995-d2ee-5294-be4f-228c597ef0fd
DOI: 10.64898/2026.08.28.747876

Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest

Development and Optimization of 111In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma ResectionDOI 10.64898/2026.08.28.747876Read

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumorsSemantic proximity Read

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity TargetingSemantic proximity Read

Combination of minimal residual disease and 123 I-Metaiodobenzylguanidine scintigraphy in monitoring of neuroblastoma metastasesSemantic proximity Read

Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work BetterSemantic proximity Read

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read

Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector PlatformSemantic proximity Read

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Semantic proximity Read